DataMeds AI Signs Nonbinding Deal to License and Acquire Healthcare IP

• DataMeds AI entered an amended, nonbinding agreement dated October 19, 2026, to acquire and license healthcare intellectual property.
• Proposed acquisitions cover EOS Technology Holdings’ medication delivery patents and Scilex’s wearable-based drug-response verification patents.
• Licensing plans include expanded healthcare rights from Datavault AI and exclusive patient-outcomes technology from Data Health Partners.
• Closing is targeted for the fourth quarter of 2026, subject to definitive agreements, due diligence and Nasdaq requirements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DataMeds AI Inc. published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.